JP2023519640A - 脱最適化されたＳＡＲＳ－ＣｏＶ－２ならびにその方法および使用 - Google Patents

脱最適化されたＳＡＲＳ－ＣｏＶ－２ならびにその方法および使用 Download PDF

Info

Publication number
JP2023519640A
JP2023519640A JP2022572258A JP2022572258A JP2023519640A JP 2023519640 A JP2023519640 A JP 2023519640A JP 2022572258 A JP2022572258 A JP 2022572258A JP 2022572258 A JP2022572258 A JP 2022572258A JP 2023519640 A JP2023519640 A JP 2023519640A
Authority
JP
Japan
Prior art keywords
cov
sars
coronavirus
polynucleotide
various embodiments
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022572258A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023519640A5 (enExample
Inventor
シュテフェン ミュラー
ジョン ロバート コールマン
イン ワン
チェン ヤン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Codagenix Inc
Original Assignee
Codagenix Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Codagenix Inc filed Critical Codagenix Inc
Publication of JP2023519640A publication Critical patent/JP2023519640A/ja
Publication of JP2023519640A5 publication Critical patent/JP2023519640A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20051—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20071—Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • Fats And Perfumes (AREA)
  • Peptides Or Proteins (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Saccharide Compounds (AREA)
JP2022572258A 2020-01-28 2021-01-27 脱最適化されたＳＡＲＳ－ＣｏＶ－２ならびにその方法および使用 Pending JP2023519640A (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US202062966750P 2020-01-28 2020-01-28
US62/966,750 2020-01-28
US202063048942P 2020-07-07 2020-07-07
US63/048,942 2020-07-07
US202063079337P 2020-09-16 2020-09-16
US63/079,337 2020-09-16
US202063079853P 2020-09-17 2020-09-17
US63/079,853 2020-09-17
PCT/US2021/015246 WO2021154828A1 (en) 2020-01-28 2021-01-27 DEOPTIMIZED SARS-CoV-2 AND METHODS AND USES THEREOF

Publications (2)

Publication Number Publication Date
JP2023519640A true JP2023519640A (ja) 2023-05-11
JP2023519640A5 JP2023519640A5 (enExample) 2024-02-06

Family

ID=77078567

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022572258A Pending JP2023519640A (ja) 2020-01-28 2021-01-27 脱最適化されたＳＡＲＳ－ＣｏＶ－２ならびにその方法および使用

Country Status (17)

Country Link
US (1) US20230117167A1 (enExample)
EP (1) EP4096712A4 (enExample)
JP (1) JP2023519640A (enExample)
KR (1) KR20220132588A (enExample)
CN (1) CN115427073A (enExample)
AU (1) AU2021213121A1 (enExample)
BR (1) BR112022014700A2 (enExample)
CA (1) CA3168100A1 (enExample)
CL (1) CL2022002030A1 (enExample)
CO (1) CO2022010743A2 (enExample)
IL (1) IL295112A (enExample)
MX (1) MX2022009099A (enExample)
PE (1) PE20230166A1 (enExample)
PH (1) PH12022551788A1 (enExample)
SA (1) SA522433428B1 (enExample)
TW (1) TW202144570A (enExample)
WO (1) WO2021154828A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12194089B2 (en) 2020-02-04 2025-01-14 CureVac SE Coronavirus vaccine
US11241493B2 (en) 2020-02-04 2022-02-08 Curevac Ag Coronavirus vaccine
US12029786B2 (en) * 2020-02-07 2024-07-09 RNAimmune, Inc. Composition and method of mRNA vaccines against novel coronavirus infection
US20230057087A1 (en) * 2020-03-06 2023-02-23 Genomictree, Inc. Composition for diagnosing sars-cov-2, kit, and method for diagnosing sars-cov-2 by using same
US12558415B2 (en) * 2020-04-14 2026-02-24 The Regents Of The University Of California Broad-spectrum multi-antigen pan-coronavirus vaccine
EP4181956A4 (en) * 2020-07-16 2024-08-07 Griffith University VACCINE AGAINST A LIVE ATTENUATED VIRUS
US11918643B2 (en) 2020-12-22 2024-03-05 CureVac SE RNA vaccine against SARS-CoV-2 variants
JP2024530672A (ja) 2021-08-11 2024-08-23 アールエヌエーイミューン、インコーポレイテッド 新規なコロナウイルス感染症に対するｍＲＮＡワクチンの組成物および方法
WO2023037387A2 (en) 2021-09-08 2023-03-16 Serum Institute Of India Private Limited Freeze-dried viral combination vaccine compositions and process for preparation thereof
EP4466014A1 (en) * 2022-01-20 2024-11-27 Freie Universität Berlin A live attenuated sars-cov-2 and a vaccine made thereof
WO2023186946A1 (en) * 2022-03-28 2023-10-05 Universität Bern One-to-stop attenuated sars-cov-2 virus
EP4331602A1 (en) * 2022-09-05 2024-03-06 Freie Universität Berlin A live attenuated sars-cov-2 and a vaccine made thereof
KR20250060275A (ko) 2022-09-05 2025-05-07 프라이 유니베르시탯 베를린 살아있는 약독화된 SARS-CoV-2 및 이의 제조 백신
CN120676963A (zh) * 2022-10-12 2025-09-19 伯尔尼大学 使用一至终止减毒的SARS-CoV-2病毒的治疗
EP4608442A1 (en) 2022-10-28 2025-09-03 GlaxoSmithKline Biologicals S.A. Nucleic acid based vaccine
US12280104B2 (en) 2022-11-01 2025-04-22 RNAimmune, Inc. Composition and methods for MRNA vaccines against novel omicron coronavirus infections
WO2025081050A1 (en) * 2023-10-13 2025-04-17 Duke University Coronavirus stem helix and fusion peptide nanoparticle vaccines

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080118530A1 (en) * 2004-10-08 2008-05-22 Kew Olen M Modulation of Replicative Fitness By Deoptimization of Synonymous Codons
JP2010523086A (ja) * 2007-03-30 2010-07-15 ザ・リサーチ・ファウンデーション・オブ・ステート・ユニヴァーシティー・オブ・ニュー・ヨーク ワクチンに有用な弱毒化ウイルス
JP2018537103A (ja) * 2015-12-11 2018-12-20 ザ ユナイテッド ステイツ オブ アメリカ アズ リプリゼンテッド バイ ザ セクレタリー、デパートメント オブ ヘルス アンド ヒューマン サービシーズＴｈｅ Ｕ．Ｓ．Ａ．Ａｓ Ｒｅｐｒｅｓｅｎｔｅｄ Ｂｙ Ｔｈｅ Ｓｅｃｒｅｔａｒｙ，Ｄｅｐａｒｔｍｅｎｔ Ｏｆ Ｈｅａｌｔｈ Ａｎｄ Ｈｕｍａｎ Ｓｅｒｖｉｃｅｓ Ｎｓ１およびｎｓ２遺伝子シフトを含む組換えｒｓウイルス株
JP2021500880A (ja) * 2017-10-16 2021-01-14 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム ２つの発現カセットを有するサルアデノウイルスベクター

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7339051B2 (en) * 2003-04-28 2008-03-04 Isis Pharmaceuticals, Inc. Compositions and methods for the treatment of severe acute respiratory syndrome (SARS)
US20120269849A1 (en) * 2009-10-09 2012-10-25 Eckard Wimmer Attenuated influenza viruses and vaccines
KR20260047644A (ko) * 2017-03-30 2026-04-08 더 유니버서티 어브 퀸슬랜드 키메라 분자 및 그의 용도

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080118530A1 (en) * 2004-10-08 2008-05-22 Kew Olen M Modulation of Replicative Fitness By Deoptimization of Synonymous Codons
JP2010523086A (ja) * 2007-03-30 2010-07-15 ザ・リサーチ・ファウンデーション・オブ・ステート・ユニヴァーシティー・オブ・ニュー・ヨーク ワクチンに有用な弱毒化ウイルス
JP2018537103A (ja) * 2015-12-11 2018-12-20 ザ ユナイテッド ステイツ オブ アメリカ アズ リプリゼンテッド バイ ザ セクレタリー、デパートメント オブ ヘルス アンド ヒューマン サービシーズＴｈｅ Ｕ．Ｓ．Ａ．Ａｓ Ｒｅｐｒｅｓｅｎｔｅｄ Ｂｙ Ｔｈｅ Ｓｅｃｒｅｔａｒｙ，Ｄｅｐａｒｔｍｅｎｔ Ｏｆ Ｈｅａｌｔｈ Ａｎｄ Ｈｕｍａｎ Ｓｅｒｖｉｃｅｓ Ｎｓ１およびｎｓ２遺伝子シフトを含む組換えｒｓウイルス株
JP2021500880A (ja) * 2017-10-16 2021-01-14 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム ２つの発現カセットを有するサルアデノウイルスベクター

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
"Betacoronavirus sp. isolate Wuhan-Hu-1, complete genome", DATABASE DDBJ/EMBL/GENBANK [ONLINE]，ACCESSION NO.MN908947.1, vol. [検索日 2024.12.17], JPN6024052211, 12 January 2020 (2020-01-12), ISSN: 0005607484 *

Also Published As

Publication number Publication date
AU2021213121A1 (en) 2022-08-18
PE20230166A1 (es) 2023-02-01
CA3168100A1 (en) 2021-08-05
MX2022009099A (es) 2022-10-20
CO2022010743A2 (es) 2022-08-30
WO2021154828A1 (en) 2021-08-05
BR112022014700A2 (pt) 2022-10-11
CN115427073A (zh) 2022-12-02
TW202144570A (zh) 2021-12-01
US20230117167A1 (en) 2023-04-20
KR20220132588A (ko) 2022-09-30
EP4096712A4 (en) 2024-05-08
SA522433428B1 (ar) 2024-10-08
CL2022002030A1 (es) 2023-03-10
EP4096712A1 (en) 2022-12-07
PH12022551788A1 (en) 2024-02-26
IL295112A (en) 2022-09-01

Similar Documents

Publication Publication Date Title
JP2023519640A (ja) 脱最適化されたＳＡＲＳ－ＣｏＶ－２ならびにその方法および使用
US20220378904A1 (en) Hmpv mrna vaccine composition
US20240299525A1 (en) Rsv rna vaccines
US20230381301A1 (en) Respiratory virus nucleic acid vaccines
US20230338506A1 (en) Respiratory virus immunizing compositions
WO2021222304A1 (en) Sars-cov-2 rna vaccines
US20200030432A1 (en) Zoonotic disease rna vaccines
Ye et al. Intranasal administration of a single dose of a candidate live attenuated vaccine derived from an NSP16-deficient SARS-CoV-2 strain confers sterilizing immunity in animals
EP3233890B1 (en) Pestivirus
Ludlow Respiratory syncytial virus infection in the modern era
Le Nouën et al. Optimization of the codon pair usage of human respiratory syncytial virus paradoxically resulted in reduced viral replication in vivo and reduced immunogenicity
US20240299533A1 (en) Deoptimized sars-cov-2 variants and methods and uses thereof
CN109476708B (zh) 针对致关节炎甲病毒的疫苗
Azab et al. Comparative efficacy of a field-strain matched bivalent inactivated vaccine against contemporary newcastle disease and infectious bronchitis viruses in Egypt
US20220088169A1 (en) Virus vaccine
MX2015000789A (es) Composiciones de virus de la gripe bovina.
WO2018146257A1 (en) Hepatitis e virus vaccine
WO2025149032A1 (en) Respiratory syncytial virus vaccine compositions and their use
Enterovirus Jorge CG Blanco1✉, Fatoumata YD Sylla1, Sandra Granados1, Alessio Noghero2, Marina S. Boukhvalova1 & Adriana E. Kajon2
Dang et al. MGF100 but not MGF300 family is a potential multigene-deleted target for ASFV attenuation and live attenuated vaccine development
Shatnawi Translational Feline Models for Immunopathogenesis and Vaccine Efficacy Against SARS-CoV-2 Variants
Wang et al. Comparison of efficacy, safety, immune response of dNS1 LAIV and cold-adapted LAIV in a mouse model
CN118873661A (zh) Hs2st1基因／蛋白作为靶点在筛选预防或治疗塞内卡病毒感染的药物中的用途
HK40095771A (zh) 预防突变株的新型冠状病毒mRNA疫苗
Wiselka Respiratory virus infection in chronic chest disease

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221102

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20230823

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240126

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240126

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20241224

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20241225

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250321

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250602